In a first, more adult patients living with certain forms of blood cancer will now be able to access CAR T-cell therapy on the UK’s National Health Service (NHS).
US biotech major Gilead Sciences (Nasdaq: GILD) and its Kite subsidiary announced that the National Institute for Health and Care Excellence (NICE) has recommended additional uses for its two CAR T-cell therapies as options for the treatment of certain blood cancers, within the Cancer Drugs Fund (CDF).
As the leading cell therapy company, Kite has two CAR T-cell therapies now available on the NHS for four types of blood cancer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze